Skip to content

Raptor Pharmaceutical Corp: 10-Q filed 2012-04-09

What Raptor Pharmaceutical Corp reported in its quarterly report filed 2012-04-09 (fiscal Q2 2012): 30 published measures, 90 facts as tagged in accession 0001193125-12-155097.

This filing

Form
10-Q (quarterly report)
Filed
2012-04-09
Fiscal period
fiscal Q2 2012
Accession
0001193125-12-155097 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Raptor Pharmaceutical Corp filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2012-02-2959,215,372USD
At 2011-08-3122,562,504USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2012-02-2930,069,284USD
At 2011-08-3126,709,552USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2012-02-2929,146,088USD
At 2011-08-31-4,147,048USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2012-02-2919,689,438USD
At 2011-08-3115,172,086USD
At 2011-02-2816,480,598USD
At 2010-08-3116,953,524USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2011-12-01 to 2012-02-29-13,992,159USD91
2011-09-01 to 2012-02-29-25,425,017USD182
2005-09-08 to 2012-02-29-103,426,621USD2366
2010-12-01 to 2011-02-28-2,974,294USD90
2010-09-01 to 2011-02-28-13,095,071USD181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2011-09-01 to 2012-02-29-12,971,464USD182
2005-09-08 to 2012-02-29-61,334,158USD2366
2010-09-01 to 2011-02-28-7,643,241USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2011-09-01 to 2012-02-2947,865,079USD182
2005-09-08 to 2012-02-29111,477,558USD2366
2010-09-01 to 2011-02-287,303,514USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2011-09-01 to 2012-02-29-30,369,380USD182
2005-09-08 to 2012-02-29-30,448,983USD2366
2010-09-01 to 2011-02-28-138,748USD181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2012-02-29223,446USD
At 2011-08-3176,997USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2011-09-01 to 2012-02-292,021,039USD182
2005-09-08 to 2012-02-295,372,401USD2366
2010-09-01 to 2011-02-281,179,562USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2011-12-01 to 2012-02-29-6,423,889USD91
2011-09-01 to 2012-02-29-13,776,356USD182
2005-09-08 to 2012-02-29-69,867,669USD2366
2010-12-01 to 2011-02-28-4,795,758USD90
2010-09-01 to 2011-02-28-9,196,987USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2012-02-2952,433,700USD
At 2011-08-3115,702,498USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2011-12-01 to 2012-02-29212USD91
2011-09-01 to 2012-02-29717USD182
2005-09-08 to 2012-02-29116,847USD2366
2010-12-01 to 2011-02-28356USD90
2010-09-01 to 2011-02-28998USD181

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2012-02-2930,061,570USD
At 2011-08-3126,699,774USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2012-02-291,087,186USD
At 2011-08-31847,137USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2012-02-293,275,403USD
At 2011-08-313,275,403USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2011-12-01 to 2012-02-296,423,889USD91
2011-09-01 to 2012-02-2913,776,356USD182
2005-09-08 to 2012-02-2969,867,669USD2366
2010-12-01 to 2011-02-284,795,758USD90
2010-09-01 to 2011-02-289,196,987USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2011-12-01 to 2012-02-293,971,471USD91
2011-09-01 to 2012-02-298,987,650USD182
2005-09-08 to 2012-02-2948,224,940USD2366
2010-12-01 to 2011-02-283,669,246USD90
2010-09-01 to 2011-02-286,364,375USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2012-02-2948,854,168shares
At 2011-08-3135,569,188shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2012-02-29132,528,834USD
At 2011-08-3173,817,083USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2012-02-29-4,979USD
At 2011-08-311,904USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2012-02-293,177,917USD
At 2011-08-313,250,917USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2012-02-292,375,832USD
At 2011-08-312,249,254USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2012-02-292,339,667USD
At 2011-08-31415,944USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2011-12-01 to 2012-02-29-13,993,748USD91
2011-09-01 to 2012-02-29-25,431,900USD182
2005-09-08 to 2012-02-29-103,431,600USD2366
2010-12-01 to 2011-02-28-2,972,256USD90
2010-09-01 to 2011-02-28-13,089,522USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2011-12-01 to 2012-02-292,452,418USD91
2011-09-01 to 2012-02-294,788,706USD182
2005-09-08 to 2012-02-2921,642,729USD2366
2010-12-01 to 2011-02-281,126,512USD90
2010-09-01 to 2011-02-282,832,612USD181

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2011-09-01 to 2012-02-2917,964USD182
2005-09-08 to 2012-02-29518,737USD2366
2010-09-01 to 2011-02-2839,441USD181

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2011-09-01 to 2012-02-2973,000USD182
2005-09-08 to 2012-02-29623,958USD2366
2010-09-01 to 2011-02-2876,750USD181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2011-09-01 to 2012-02-2946,000,000USD182
2005-09-08 to 2012-02-2985,941,278USD2366

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2011-09-01 to 2012-02-29240,049USD182
2005-09-08 to 2012-02-291,087,186USD2366
2010-09-01 to 2011-02-2877,325USD181

Inspect the source

Entity
Raptor Pharmaceutical Corp / CIK 0001070698
Captured
SEC response SHA-256
621cb173f749d501d2fb5aa6b3467429c1c69194ff3b9f764c3204f6f9dda50e

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001070698.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))